Combination Therapy in Cancer

Abstract

There has been a dramatic increase in the number of treatment approaches that can be used to manage patients with cancer. They range from those that are conventionally cytotoxic in nature to those that have been specifically designed with a particular target in mind. Although these ‘intelligent’ drugs successfully perform their intended function, their action can be more diverse than first anticipated. This is often the case with more conventional chemotherapies, where secondary effects are overlooked as the focus is rightly on the principal effect. For example, in addition to its more classic cytotoxic effect, gemcitabine is capable of increasing the antigenicity of tumours, causing them to become more visible to the immune system. It is this continued search for novel ways to exploit drugs that are already available that will increase the pool of treatment options available to patients.

Key Concepts

  • Pairing up treatment modalities can enhance the overall effect of each drug.
  • Certain immune therapies support chemotherapy.
  • Targeting multiple signalling pathways in cancer cells can improve overall activity.
  • Altering the tumour phenotype to restore visibility to the immune system can be achieved through the use of certain chemotherapy.
  • The sequence that drugs are given can affect overall drug combination efficacy.

Keywords: combination therapy; chemotherapy; immune therapy; drug schedule; sequence

References

Abbas AK, Murphy KM and Sher A (1996) Functional diversity of helper T lymphocytes. Nature 383 (6603): 787–793.

Alexander W (2011) Inhibiting the akt pathway in cancer treatment: three leading candidates. P & T: A Peer‐Reviewed Journal for Formulary Management 36 (4): 225–227.

Apperley JF (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncology 8 (11): 1018–1029.

Champoux JJ (2001) DNA topoisomerases: structure, function, and mechanism. Annual Review of Biochemistry 70: 369–413.

Cheng JQ, Lindsley CW, Cheng GZ, et al. (2005) The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24 (50): 7482–7492.

Chou TC (2010) Drug combination studies and their synergy quantification using the Chou‐Talalay method. Cancer Research 70 (2): 440–446.

Ciocca DR and Calderwood SK (2005) Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress & Chaperones 10 (2): 86–103.

Dalgleish AG and O'Byrne KJ (2002) Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer. Advances in Cancer Research 84: 231–276.

Daub H, Specht K and Ullrich A (2004) Strategies to overcome resistance to targeted protein kinase inhibitors. Nature Reviews. Drug Discovery 3 (12): 1001–1010.

DeVita VT Jr and Chu E (2008) A history of cancer chemotherapy. Cancer Research 68 (21): 8643–8653.

Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nature Reviews. Cancer 3 (1): 11–22.

Druker BJ, Tamura S, Buchdunger E, et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr‐Abl positive cells. Nature Medicine 2 (5): 561–566.

Dunn GP, Bruce AT, Ikeda H, et al. (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology 3 (11): 991–998.

Fowler DW, Copier J, Wilson N, et al. (2012) Mycobacteria activate γδ T‐cell anti‐tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy. Cancer Immunology, Immunotherapy 61 (4): 535–547.

Goldenberg MM (1999) Trastuzumab, a recombinant DNA‐derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clinical Therapeutics 21 (2): 309–318.

Gorre ME, Mohammed M, Ellwood K, et al. (2001) Clinical resistance to STI‐571 cancer therapy caused by BCR‐ABL gene mutation or amplification. Science 293 (5531): 876–880.

Hodi FS, O'Day SJ, McDermott DF, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine 363 (8): 711–723.

Komarova NL and Boland CR (2013) Cancer: calculated treatment. Nature 499 (7458): 291–292.

Li F, Zhao C and Wang L (2014) Molecular‐targeted agents combination therapy for cancer: developments and potentials. International Journal of Cancer 134 (6): 1257–1269.

Liu WM, Fowler DW, Gravett AM, et al. (2011) Supernatants from lymphocytes stimulated with Bacillus Calmette‐Guerin can modify the antigenicity of tumours and stimulate allogeneic T‐cell responses. British Journal of Cancer 105 (5): 687–693.

Liu WM and Dalgleish AG (2012) The potential beneficial effects of drugs on the immune response to vaccination. Seminars in Oncology 39 (3): 340–347.

Liu WM, Fowler DW, Smith P and Dalgleish AG (2010) Pre‐treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. British Journal of Cancer 102 (1): 115–123.

Makin G and Dive C (2003) Recent advances in understanding apoptosis: new therapeutic opportunities in cancer chemotherapy. Trends in Molecular Medicine 9 (6): 251–255.

Matsushita N, Pilon‐Thomas SA, Martin LM, et al. (2008) Comparative methodologies of regulatory T cell depletion in a murine melanoma model. Journal of Immunological Methods 333 (1–2): 167–179.

Nowak AK, Robinson BW and Lake RA (2002) Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo‐immunotherapy. Cancer Research 62 (8): 2353–2358.

Pardoll DM (1999) Inducing autoimmune disease to treat cancer. Proceedings of the National Academy of Sciences of the United States of America 96 (10): 5340–5342.

Pilones KA, Vanpouille‐Box C and Demaria S (2015) Combination of radiotherapy and immune checkpoint inhibitors. Seminars in Radiation Oncology 25 (1): 28–33.

Plate JM, Plate AE, Shott S, et al. (2005) Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunology, Immunotherapy 54 (9): 915–925.

Redelman‐Sidi G, Glickman MS and Bochner BH (2014) The mechanism of action of BCG therapy for bladder cancer–a current perspective. Nature Reviews. Urology 11 (3): 153–162.

Reed JC (1999) Dysregulation of apoptosis in cancer. Journal of Clinical Oncology 17 (9): 2941–2953.

Seliger B, Ruiz‐Cabello F and Garrido F (2008) IFN inducibility of major histocompatibility antigens in tumors. Advances in Cancer Research 101: 249–276.

Shah NP, Tran C, Lee FY, et al. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (5682): 399–401.

Sharma SV and Settleman J (2007) Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes and Development 21 (24): 3214–3231.

Tang C, Wang X, Soh H, et al. (2014) Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunology Research 2 (9): 831–838.

Topalian SL, Hodi FS, Brahmer JR, et al. (2012) Safety, activity, and immune correlates of anti‐PD‐1 antibody in cancer. New England Journal of Medicine 366 (26): 2443–2454.

Twyman‐Saint Victor C, Rech AJ, Maity A, et al. (2015) Radiation and dual checkpoint blockade activate non‐redundant immune mechanisms in cancer. Nature 520 (7547): 373–377.

Vanneman M and Dranoff G (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nature Reviews. Cancer 12 (4): 237–251.

Wargo JA, Reuben A, Cooper ZA, et al. (2015) Immune effects of chemotherapy, radiation, and targeted therapy and opportunities for combination with immunotherapy. Seminars in Oncology 42 (4): 601–616.

Weiner LM, Dhodapkar MV and Ferrone S (2009) Monoclonal antibodies for cancer immunotherapy. Lancet 373 (9668): 1033–1040.

Yang J and Yi Q (2010) Killing tumor cells through their surface beta(2)‐microglobulin or major histocompatibility complex class I molecules. Cancer 116 (7): 1638–1645.

Further Reading

Dalgleish AG (2015) Rationale for combining immunotherapy with chemotherapy. Immunotherapy 7 (3): 309–316.

Liu WM and Dalgleish AG (2012) Cancer cell‐derived supernatants that support the carcinogenic process: a future cancer therapy target? Future Oncology 8 (7): 767–769.

Melero I, Berman DM, Aznar MA, et al. (2015) Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nature Reviews. Cancer 15 (8): 457–472.

Miller MJ, Foy KC and Kaumaya PT (2013) Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics. Discovery Medicine 15 (82): 166–176.

Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews. Cancer 12 (4): 252–264.

Sharma P and Allison JP (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161 (2): 205–214.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Liu, Wai M, Scott, Katherine A, and Dalgleish, Angus G(Apr 2016) Combination Therapy in Cancer. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0026247]